<DOC>
	<DOCNO>NCT01032291</DOCNO>
	<brief_summary>The purpose study determine whether lenalidomide combination cetuximab safe effective patient KRAS mutant colorectal cancer .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety Lenalidomide Combination With Cetuximab Pre-treated Patients With KRAS Mutant Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Metastatic colorectal adenocarcinoma . 2 . Confirmed KRAS mutant tumor 3 . Disease progression oxaliplatin AND irinotecancontaining regimen , least one regimens contain bevacizumab . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 . 1 . Use chemotherapy , hormonal therapy , immunotherapy cancer experimental treatment ≤ 28 day prior first day first cycle . 2 . Radiotherapy ≥ 30 % bone marrow . 3 . Surgery ≤ 28 day day 1 first cycle ( minimally invasive intervention diagnostic purpose disease stag permit ) . 4 . Previous treatment cetuximab , panitumumab , pomalidomide ( CC4047 ) , lenalidomide thalidomide . 5 . Untreated , symptomatic brain metastasis ( brain imaging require ) . 6 . Venous thromboembolism ≤ 6 month day1 first cycle . 7 . Current congestive heart failure ( class II IV New York Heart Association ) . 8 . Myocardial infarction ≤ 12 month day1 first cycle . 9 . Uncontrolled hypertension .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Erbitux</keyword>
	<keyword>KRAS</keyword>
</DOC>